4D Molecular Therapeutics, Inc. (FDMT) › Operating Income4D Molecular Therapeutics, Inc. (FDMT) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2019: -$50.76M2020: -$56.66M2021: -$71.33M2022: -$110.03M2023: -$112.87M2024: -$187.84M2025: -$159.55M-$159.55M2019Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$159.55M+15.1%2024-$187.84M-66.4%2023-$112.87M-2.6%2022-$110.03M-54.3%2021-$71.33M-25.9%2020-$56.66M-11.6%2019-$50.76M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share